UltiMed. Revenue and Competitors
Estimated Revenue & Valuation
- UltiMed.'s estimated annual revenue is currently $14.1M per year.
- UltiMed.'s estimated revenue per employee is $251,000
Employee Data
- UltiMed. has 56 Employees.
- UltiMed. grew their employee count by -10% last year.
UltiMed.'s People
| Name | Title | Email/Phone |
|---|
UltiMed. Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $30.6M | 122 | 4% | N/A | N/A |
#2 | $18.6M | 74 | 35% | N/A | N/A |
#3 | $75.6M | 301 | 20% | N/A | N/A |
#4 | $12M | 48 | 4% | N/A | N/A |
#5 | $2.8M | 11 | 10% | N/A | N/A |
#6 | $3M | 12 | 0% | N/A | N/A |
#7 | $24.6M | 98 | 5% | N/A | N/A |
#8 | $11.5M | 46 | 21% | N/A | N/A |
#9 | $7.3M | 29 | 4% | N/A | N/A |
#10 | $13.8M | 55 | -10% | N/A | N/A |
What Is UltiMed.?
Ulti Care™ is the registered trade name of Ulti Med Inc. Ulti Med Inc. has over 10 years of experience in the hospital and wholesale syringe business. We have two factories for syringe and needle production, one in DeSmet, South Dakota, and the other in Kong Ju, Korea. UltiMed’s U. S. factory opened in 2001 and is the most modern in the United States. This facilty specializes in insulin syringes for the diabetes market. Our Korean factory is the largest syringe and needle only manufacturer in Korea, employing 115 people. All phases of syringe manufacturing are done on fully automated machinery, including injection molding, needle grinding, assembly and sterilization.
keywords:N/A
N/A
Total Funding
56
Number of Employees
$14.1M
Revenue (est)
-10%
Employee Growth %
N/A
Valuation
N/A
Accelerator
UltiMed. News
UltiMed; Boehringer Ingelheim Vetmedica; Apotex; Zoetis; Merck; FitBark; BD; Henry Schein Animal Health. Pet Diabetes Care Market Breakdown by Type:.
... And Forecast | Zoetis, Abbott, Woodley Equipment Company Ltd., Nova Biomedical, BioNote Inc., Arkray, UltiMed, Medray, Biotest Medical Corp., Zoetis.
Pen Needles Market: Global Industry Analysis and Opportunity Assessment 2022-2029 | Top Key Vendors BD, GSK, Terumo, UltiMed, AstraZeneca.
Other Companies in Shorewood
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $1.7M | 64 | 5% | N/A |
#2 | $15.1M | 74 | 4% | N/A |
#3 | $27.7M | 132 | 16% | N/A |